Table 2 Individual performance of each of the 16 candidate MDMs in plasma by AUC (95% confidence interval)
From: Plasma assay of methylated DNA markers detects recurrent metastatic breast cancer
AUC (95% CI) | |||
|---|---|---|---|
Marker | Benign vs MBC | NED vs MBC | Both vs MBC |
MDM1 | 0.96 (0.93–1.00) | 0.96 (0.93–1.00) | 0.96 (0.93–1.00) |
MDM6 | 0.95 (0.91–0.99) | 0.96 (0.92–0.99) | 0.95 (0.92–0.99) |
MDM5 | 0.95 (0.91–0.99) | 0.95 (0.91–0.99) | 0.95 (0.91–0.99) |
MDM8 | 0.94 (0.90–0.98) | 0.94 (0.90-0.98) | 0.94 (0.90–0.98) |
MDM13 | 0.94 (0.90–0.98) | 0.94 (0.90–0.98) | 0.94 (0.90–0.98) |
MDM7 | 0.94 (0.89–0.98) | 0.94 (0.89–0.98) | 0.94 (0.89–0.98) |
MDM9 | 0.94 (0.89–0.98) | 0.93 (0.88–0.98) | 0.93 (0.89–0.98) |
MDM2 | 0.93 (0.88–0.98) | 0.93 (0.88–0.98) | 0.93 (0.88–0.98) |
MDM10 | 0.92 (0.88–0.97) | 0.91 (0.86–0.97) | 0.92 (0.87–0.97) |
MDM3 | 0.93 (0.87–0.98) | 0.90 (0.84–0.96) | 0.91 (0.86–0.97) |
MDM14 | 0.91 (0.85–0.97) | 0.90 (0.84–0.96) | 0.91 (0.85–0.96) |
MDM11 | 0.88 (0.81–0.94) | 0.86 (0.79–0.93) | 0.87 (0.80–0.93) |
MDM12 | 0.88 (0.82–0.94) | 0.84 (0.76–0.91) | 0.86 (0.80–0.92) |
CA153 (protein) | 0.86 (0.78–0.93) | 0.86 (0.79–0.93) | 0.86 (0.79–0.92) |
MDM4 | 0.84 (0.77–0.91) | 0.86 (0.79–0.93) | 0.85 (0.78–0.92) |
MDM15 | 0.85 (0.78–0.92) | 0.84 (0.76–0.91) | 0.84 (0.77–0.92) |
CEA (protein) | 0.86(0.79-0.92) | 0.81 (0.74–0.89) | 0.84 (0.77–0.90) |
MDM16 | 0.84 (0.76–0.91) | 0.79 (0.70–0.87) | 0.81 (0.74–0.89) |
CA125 (protein) | 0.77 (0.68–0.85) | 0.74 (0.65–0.83) | 0.75 (0.67–0.84) |
